^“FDA approves new treatment for rare form of thyroid cancer”. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm250168.htm2011年4月7日閲覧。[リンク切れ]
^“FDA approves orphan drug vandetanib for advanced medullary thyroid cancer” (プレスリリース), AstraZeneca, http://www.astrazeneca-us.com/about-astrazeneca-us/newsroom/all/12149869?itemId=121498692011年8月17日閲覧。[リンク切れ]
^“AstraZeneca announces trade name CAPRELSA for vandetanib” (プレスリリース), AstraZeneca, http://www.astrazeneca-us.com/about-astrazeneca-us/newsroom/all/12379191?itemId=123791912011年8月17日閲覧。[リンク切れ]
^ abKhurana V, Minocha M, Pal D, Mitra AK (March 2014). “Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors.”. Drug Metabol Drug Interact.0 (0): 1–11. doi:10.1515/dmdi-2013-0062. PMID 24643910.
^ abcHaberfeld, H, ed (2012) (German). Austria-Codex. Vienna: Österreichischer Apothekerverlag.
^Khurana V, Minocha M, Pal D, Mitra AK (May 2014). “Inhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitors.”. Drug Metabol Drug Interact.0 (0): 1-11. doi:10.1515/dmdi-2014-0014. PMID 24807167.
^ ab“Clinical Pharmacology Review: Vandetanib”. US Food and Drug Administration, Center for Drug Evaluation and Research (2010年8月20日). 2012年8月29日閲覧。
^Martin, P.; Oliver, S.; Kennedy, S. J.; Partridge, E.; Hutchison, M.; Clarke, D.; Giles, P. (2012). “Pharmacokinetics of Vandetanib: Three Phase I Studies in Healthy Subjects”. Clinical Therapeutics34 (1): 221–237. doi:10.1016/j.clinthera.2011.11.011. PMID 22206795.
^“Vandetanib Shows Clinical Benefit When Combined With Docetaxel For Lung Cancer”. ScienceDaily. (2009年6月3日). http://www.sciencedaily.com/releases/2009/06/090601092237.htm
^“IASLC: Vandetanib Fails to Improve NSCLC Outcomes with Pemetrexed”. Medpage today. (2009年8月5日). http://www.medpagetoday.com/MeetingCoverage/IASLC/15396
^臨床試験番号 NCT00687297 研究名 "Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer" - ClinicalTrials.gov
^“Zactima”. European Medicines Agency. 2010年12月2日閲覧。
外部リンク
Cancerline.com: Vandetanib Information for Physicians[リンク切れ]
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
…patients randomly assigned to vandetanib versus placebo (hazard ratio [HR] 0.46, 95% CI 0.31-0.69) . The median progression-free survival had not yet been reached for the vandetanib group but was predicted to …
… including . Vandetanib is an orally active inhibitor of several tyrosine kinases, including RET, VEGFR, and endothelial growth factor receptor (EGFR). As noted in the for vandetanib, increases in creatinine …
…months) . Largely because of its cardiovascular risk, vandetanib is only available through a restricted distribution program (the ). Vandetanib should not be initiated in a patient with a QTc interval …
…reported in 30 to 79 percent of patients (highest rates with vandetanib), with severe diarrhea (grade 3 or 4) in 3 to 17 percent . Vandetanib is a moderately potent epidermal growth factor receptor (EGFR) …
…and/or immunotherapy, we suggest treatment with an off-label RET inhibitor such as cabozantinib, vandetanib, or alectinib. In a phase II trial of cabozantinib including 25 evaluable patients, all of whom …